Healthcare Personnel
Recently Published Documents


TOTAL DOCUMENTS

957
(FIVE YEARS 647)

H-INDEX

33
(FIVE YEARS 17)

Cephalalgia ◽  
2021 ◽  
pp. 033310242110423
Author(s):  
Esme Ekizoglu ◽  
Haşim Gezegen ◽  
Pınar Yalınay Dikmen ◽  
Elif Kocasoy Orhan ◽  
Mustafa Ertaş ◽  
...  

Introduction Headache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache. Methods The characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire. Results A total of 1819 healthcare personnel (mean age: 44.4 ± 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey; 209 (11.4%) had been infected with COVID-19. A total of 556 participants (30.6%) reported headache with significant female dominance (36.1% vs. 19.3%), 1.8 ± 3.5 (median: 1; IQR: 0–2) days following vaccination. One hundred and forty-four participants (25.9%) experienced headache lasting ≥3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 [95% CI 1.74–2.68] and 1.65 [1.24–2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 [95% CI 1.82–10.2] and OR = 4.84 [95% CI 2.84–8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 [95% CI 1.15–2.08]) with vaccine-related headache among the common comorbidities. Conclusion Headache is observed in 30.6% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Laura E. Breeher ◽  
Michael E. Wolf ◽  
Holly Geyer ◽  
Todd Brinker ◽  
Christopher Tommaso ◽  
...  

Author(s):  
Robert F Potter ◽  
Eric M Ransom ◽  
Meghan A Wallace ◽  
Caitlin Johnson ◽  
Jennie H Kwon ◽  
...  

Abstract Background Saliva has garnered great interest as an alternative specimen type for molecular detection of SARS-CoV-2. Data are limited on the relative performance of different molecular methods using saliva specimens and the relative sensitivity of saliva to NP swabs. Methods To address the gap in knowledge, we enrolled symptomatic healthcare personnel (n = 250) from Barnes-Jewish Hospital/Washington University Medical Center and patients presenting to the Emergency Department with clinical symptoms compatible with COVID-19 (n = 292). We collected paired saliva specimens and NP swabs. The Lyra SARS-CoV-2 assay (Quidel, San Diego, CA) was evaluated on paired saliva and NP samples. Subsequently we compared the Simplexa COVID-19 Direct Kit (Diasorin, Cypress, CA) and a modified SalivaDirect (Yale) assay on a subset of positive and negative saliva specimens. Results The positive percent agreement between saliva and NP samples using the Lyra SARS-CoV-2 assay was 63.2%. Saliva samples had higher SARS-CoV-2 cycle threshold values compared to NP swabs (p < 0.0001). We found a 76.47% (26/34) positive percent agreement for Simplexa COVID-19 Direct Kit on saliva and a 67.6% (23/34) positive percent agreement for SalivaDirect compared to NP swab results. Conclusion These data demonstrate molecular assays have variability in performance for detection of SARS-CoV-2 in saliva.


2021 ◽  
Vol 6 (2) ◽  
pp. 109
Author(s):  
Shafizan Mohamed ◽  
Haekal Adha Al Giffari

The COVID-19 pandemic has certainly caused havoc all over the world. Governments, healthcare personnel, and the general public are all struggling to survive the health crisis. In such calamity, the media plays an important role as it is able to impact public attitude and response towards the pandemic. Malaysia and Indonesia are two neighbouring countries that are equally affected by the pandemic. These countries share the same language and geographic location, but they have distinct populations, government systems, and ethnic identities. This study compares the news framing of Covid-19 in Malaysian and Indonesian newspapers to understand how socio-political and cultural similarities and differences affect how the health crisis is framed and presented. The Star (Malaysia) and Detik (Indonesia) were chosen to be studied in this paper, with a total of 369 news pieces obtained between 60 days after the first local COVID-19 case was discovered in the respective country. The findings suggest that the framing of Malaysian online newspapers was action-oriented, whereas the framing of Indonesian online newspapers was uncertainty-oriented. In addition, Malaysian and Indonesian internet newspapers were quick to report on the Covid-19 news. Both cited the government as their primary source and addressed risk bearers as their primary focus. This shows that despite their geographical proximities, the two countries had distinct ways of covering the pandemic.


2021 ◽  
Author(s):  
Mark A. Katz ◽  
Efrat Bron Harlev ◽  
Bibiana Chazan ◽  
Michal Chowers ◽  
David Greenberg ◽  
...  

Background Methodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate real-world VE in a closely monitored population. Methods We conducted a prospective study among HCP in 6 hospitals to estimate the effectiveness of the BNT162b2 mRNA Covid-19 vaccine in preventing SARS-CoV-2 infection. Participants filled out weekly symptom questionnaires, provided weekly nasal specimens, and three serology samples - at enrollment, 30 days and 90 days. We estimated VE against PCR-confirmed SARS-CoV-2 infection using the Cox Proportional Hazards model and against a combined PCR/serology endpoint using Fishers exact test. Findings Of the 1,567 HCP enrolled between December 27, 2020 and February 15, 2021, 1,250 previously uninfected participants were included in the primary analysis; 998 (79.8%) were vaccinated with their first dose prior to or at enrollment, all with Pfizer BNT162b2 mRNA vaccine. There were four PCR-positive events among vaccinated participants, and nine among unvaccinated participants. Adjusted two-dose VE against any PCR-confirmed infection was 94.5% (95% CI: 82.6%-98.2%); adjusted two-dose VE against a combined endpoint of PCR and seroconversion for a 60-day follow-up period was 94.5% (95% CI: 63.0%-99.0%). Five PCR-positive samples from study participants were sequenced; all were alpha variant. Interpretation Our prospective VE study of HCP in Israel with rigorous weekly surveillance found very high VE for two doses of Pfizer BNT162b2 mRNA vaccine against SARS-CoV-2 during a period of predominant alpha variant circulation.


Vaccine ◽  
2021 ◽  
Author(s):  
Mark G. Thompson ◽  
Giselle Soto ◽  
Alon Perez ◽  
Gabriella Newes-Adeyim ◽  
Young M. Yoo ◽  
...  

Author(s):  
Claudia Westermann ◽  
Dana Wendeler ◽  
Albert Nienhaus

Abstract Background Hepatitis C infections (HCV) are associated with an increase in morbidity and mortality. The aim of this study is to update the results of treatment with direct-acting antiviral agents (DAAs) using a larger population of healthcare personnel (HP) and a longer observation period. Methods Secondary data analysis of DAA treatment administered to HP (with confirmed occupational acquired HCV infection) between 1 January 2014 and 30 December 2018, is based on statutory accident insurance data from Germany. The end points of the study were results of a monitoring carried out 12 and 24 weeks after the end of treatment (sustained virological response, SVR), as well as side effects and the assessment of reduced work ability after treatment. Multivariate logistic regression models were constructed to investigate predictors of SVR. Results The study population (n = 305) mainly comprised HP with a genotype 1 infection. The average age was 63 (SD 10) and 77% were female. Two thirds of the HP suffered from fibrosis or cirrhosis, and had experience of treatment. Statistically, men were significantly more likely to suffer from cirrhosis than women (60% compared to 21%, p < 0.001). The end-of-treatment response (ETR) rate was 99% and the SVR12 and SVR24 rates were 98%. Liver cirrhosis proved to be a predictor of a statistically significant reduction in success rates. Conclusion DAA treatment leads to high SVR. Early HCV treatment is associated with higher SVR.


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Wilasinee Areeruk ◽  
Keerati Chiengthong ◽  
Somsook Santibenchakul ◽  
Shina Oranratanaphan ◽  
Tarinee Manchana

This study is aimed at evaluating the results of the universal preoperative screening for COVID-19 in gynecologic cases operated on during its outbreak in a tertiary care hospital in Bangkok, Thailand. A retrospective descriptive study was done on all patients who underwent elective or emergency gynecologic surgeries during the pandemic period in Thailand (April 15 to June 5, 2020). The COVID-19 screening results by symptom-based screening, risk-based screening, and RT-PCR for COVID-19 were collected from the electronic medical records. Among 129 patients who underwent gynecologic surgeries, none had a positive RT-PCR for COVID-19. Symptom-based screening found no patients with positive symptoms for COVID-19. Risk-based screening found 4 patients (3.1%) who were in contact with suspected or confirmed COVID-19 cases and 4 patients (3.1%) who were healthcare personnel. In conclusion, routine preoperative RT-PCR for COVID-19 may need to be reconsidered among asymptomatic individuals in a low-prevalence country during the well-controlled COVID-19 situation. Larger studies are required to ascertain the benefit of universal preoperative COVID-19 testing.


Sign in / Sign up

Export Citation Format

Share Document